Vycor Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 10:46 am EST
Share
Vycor Medical, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.309969 million compared to USD 0.332087 million a year ago. Net loss was USD 0.114807 million compared to net income of USD 0.003693 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago.
For the nine months, sales was USD 0.951725 million compared to USD 1.12 million a year ago. Net loss was USD 0.288369 million compared to USD 0.2486 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Basic loss per share was USD 0.02 compared to USD 0.02 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
